FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309660462> ?p ?o ?g. }

• W4309660462 endingPage "154" @default.
• W4309660462 startingPage "154" @default.
• W4309660462 abstract "Background: Once a widely used analgesic in the United States (US), meperidine offered an alternative opioid to other opioids as a pain reliever and was widely assumed to be safer with acute pancreatitis. However, within the last two decades meperidine, has gone from a frequently used drug to being used only when patients exhibit atypical reactions to opioids (e.g., morphine and hydromorphone), to being taken off the World Health Organization List of Essential Medications and receiving strong recommendations for overall avoidance. The aim of this study was to identify changes in meperidine distribution in the US, and regional disparities as reported to the Drug Enforcement Administration’s Automation of Reports and Consolidated Orders System (DEA ARCOS) and Medicaid. Methods: Data related to meperidine distribution was obtained through ARCOS (2001–2021) and Medicaid public use files (2016–2021). Heat maps were used to visualize regional disparities in distribution by state. States outside a 95% confidence interval were statistically significant. Results: Meperidine distribution between 2001 and 2021 decreased by 97.4% (R = −0.97, p < 0.0001). There was a 34-fold state-level difference in meperidine distribution between Arkansas (16.8 mg/10 persons) and Connecticut (0.5 mg/10 persons) in 2020. Meperidine distribution in 2020 was elevated in Arkansas, Mississippi, and Alabama. In 2021, meperidine distribution was highest in Arkansas (16.7 mg/10 persons) and lowest in Connecticut (0.8 mg/10 persons). Total prescriptions of meperidine as reported by Medicaid decreased by 73.8% (R = −0.67, p = 0.045) between 2016 and 2021. Conclusion: We observed a decrease in the overall distribution of meperidine in the past two decades, with a similar recent decline in prescribing it to Medicaid enrollees. The shortage of some parenteral formulations is an important contributor to these declines, however, the most likely explanation for this global decline in use is related to an increased recognition of safety concerns related to important drug interactions and a neurotoxic metabolite. This data may reflect plans to phase out the use of this opioid, especially in the many situations where safer and more preferred opioids are available." @default.
• W4309660462 created "2022-11-29" @default.
• W4309660462 creator A5023118202 @default.
• W4309660462 creator A5028103839 @default.
• W4309660462 creator A5035221431 @default.
• W4309660462 creator A5037218390 @default.
• W4309660462 creator A5065601853 @default.
• W4309660462 creator A5067610593 @default.
• W4309660462 creator A5068788366 @default.
• W4309660462 creator A5077816088 @default.
• W4309660462 creator A5087818219 @default.
• W4309660462 date "2022-11-20" @default.
• W4309660462 modified "2023-10-14" @default.
• W4309660462 title "Pronounced Declines in Meperidine in the US: Is the End Imminent?" @default.
• W4309660462 cites W1939986938 @default.
• W4309660462 cites W2015106223 @default.
• W4309660462 cites W2051592118 @default.
• W4309660462 cites W2108262414 @default.
• W4309660462 cites W2119336416 @default.
• W4309660462 cites W2156733880 @default.
• W4309660462 cites W2211176982 @default.
• W4309660462 cites W2257575319 @default.
• W4309660462 cites W2261890046 @default.
• W4309660462 cites W2559732081 @default.
• W4309660462 cites W2593660881 @default.
• W4309660462 cites W2793837493 @default.
• W4309660462 cites W2903069810 @default.
• W4309660462 cites W2940855354 @default.
• W4309660462 cites W2974550314 @default.
• W4309660462 cites W3092922344 @default.
• W4309660462 cites W3168192969 @default.
• W4309660462 cites W3188916076 @default.
• W4309660462 cites W4200455048 @default.
• W4309660462 cites W4241984066 @default.
• W4309660462 cites W4254102713 @default.
• W4309660462 doi "https://doi.org/10.3390/pharmacy10060154" @default.
• W4309660462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36412830" @default.
• W4309660462 hasPublicationYear "2022" @default.
• W4309660462 type Work @default.
• W4309660462 citedByCount "2" @default.
• W4309660462 countsByYear W43096604622023 @default.
• W4309660462 crossrefType "journal-article" @default.
• W4309660462 hasAuthorship W4309660462A5023118202 @default.
• W4309660462 hasAuthorship W4309660462A5028103839 @default.
• W4309660462 hasAuthorship W4309660462A5035221431 @default.
• W4309660462 hasAuthorship W4309660462A5037218390 @default.
• W4309660462 hasAuthorship W4309660462A5065601853 @default.
• W4309660462 hasAuthorship W4309660462A5067610593 @default.
• W4309660462 hasAuthorship W4309660462A5068788366 @default.
• W4309660462 hasAuthorship W4309660462A5077816088 @default.
• W4309660462 hasAuthorship W4309660462A5087818219 @default.
• W4309660462 hasBestOaLocation W43096604621 @default.
• W4309660462 hasConcept C110121322 @default.
• W4309660462 hasConcept C126322002 @default.
• W4309660462 hasConcept C134306372 @default.
• W4309660462 hasConcept C160735492 @default.
• W4309660462 hasConcept C162324750 @default.
• W4309660462 hasConcept C170493617 @default.
• W4309660462 hasConcept C194828623 @default.
• W4309660462 hasConcept C2426938 @default.
• W4309660462 hasConcept C2776534028 @default.
• W4309660462 hasConcept C2778903686 @default.
• W4309660462 hasConcept C2779158186 @default.
• W4309660462 hasConcept C2780035454 @default.
• W4309660462 hasConcept C2780820201 @default.
• W4309660462 hasConcept C2781063702 @default.
• W4309660462 hasConcept C2781168792 @default.
• W4309660462 hasConcept C33923547 @default.
• W4309660462 hasConcept C42219234 @default.
• W4309660462 hasConcept C44249647 @default.
• W4309660462 hasConcept C50522688 @default.
• W4309660462 hasConcept C71924100 @default.
• W4309660462 hasConcept C98274493 @default.
• W4309660462 hasConceptScore W4309660462C110121322 @default.
• W4309660462 hasConceptScore W4309660462C126322002 @default.
• W4309660462 hasConceptScore W4309660462C134306372 @default.
• W4309660462 hasConceptScore W4309660462C160735492 @default.
• W4309660462 hasConceptScore W4309660462C162324750 @default.
• W4309660462 hasConceptScore W4309660462C170493617 @default.
• W4309660462 hasConceptScore W4309660462C194828623 @default.
• W4309660462 hasConceptScore W4309660462C2426938 @default.
• W4309660462 hasConceptScore W4309660462C2776534028 @default.
• W4309660462 hasConceptScore W4309660462C2778903686 @default.
• W4309660462 hasConceptScore W4309660462C2779158186 @default.
• W4309660462 hasConceptScore W4309660462C2780035454 @default.
• W4309660462 hasConceptScore W4309660462C2780820201 @default.
• W4309660462 hasConceptScore W4309660462C2781063702 @default.
• W4309660462 hasConceptScore W4309660462C2781168792 @default.
• W4309660462 hasConceptScore W4309660462C33923547 @default.
• W4309660462 hasConceptScore W4309660462C42219234 @default.
• W4309660462 hasConceptScore W4309660462C44249647 @default.
• W4309660462 hasConceptScore W4309660462C50522688 @default.
• W4309660462 hasConceptScore W4309660462C71924100 @default.
• W4309660462 hasConceptScore W4309660462C98274493 @default.
• W4309660462 hasFunder F4320337537 @default.
• W4309660462 hasIssue "6" @default.
• W4309660462 hasLocation W43096604621 @default.
• W4309660462 hasLocation W43096604622 @default.

• next